Prolia Efficacy Data
Fracture incidence and BMD data
Fracture Risk Reduction
Fracture incidence with Prolia treatment over 10 years in postmenopausal osteoporosis1
New vertebral fractures
Prolia
placebo
Hip fractures
Prolia
placebo
Non-vertebral fractures
Prolia
placebo
BMD data with Prolia treatment over 10 years in postmenopausal osteoporosis1
Lumbar spine BMD
Bone Mineral Density
Total hip BMD
Bone Mineral Density
Femoral neck BMD
Bone Mineral Density
ARR=absolute risk reduction; BMD=bone mineral density; FRR=fracture risk reduction; RRR=relative risk reduction
A randomized, double-blind, placebo-controlled study in postmenopausal patients with osteoporosis receiving 60 mg Prolia (n=3,902) or placebo (n=3,906) subcutaneously once every 6 months for 3 years. Subjects were between the ages of 60 and 91 years and had bone mineral density (BMD) T-scores < -2.5 and ≥ -4.0. All women received at least 1000 mg calcium and at least 400 IU vitamin D supplementation per day. 1
* Annualized yearly subject incidence.
†In women who received Prolia in the 3-year placebo-controlled phase and continued on therapy in the long-term, open-label extension.
Additional Resources
References
| 1. | Prolia Product Monograph. Amgen Canada Inc., December 21, 2022. |
